RNS & Investor News

2020

09 December
Proposed Director appointment and Director change
18 November
License and supply agreement with Genuine Health
12 October
Launch of weight management products in Australia and New Zealand
09 October
Investor presentation
08 October
Head of Quality & Operations appointment
06 October
Exclusive distribution agreement with United Italian Trading Corporation (Pte) Ltd
02 October
FDA Investigational New Drug authorisation for product containing LPLDL®
28 September
Exclusive distribution agreement
24 September
Half Year Report
22 September
License agreement for SlimBiome® Medical in the US
17 September
Distributor agreement with Ayalla Marketing
15 September
SweetBiotix sweet fibres agreement
11 August
Scientific and commercial development update
05 August
Extension of terms for OptiBiome® with OptiPharm
30 July
Extension of terms for WellBiome with Maxum Foods
23 July
Extension of terms for WellBiome® with Agropur MSI, LLC
20 July
Trading and commercial update
16 July
Extension of terms, territories and products with CTC Holding BV
14 July
Extension of terms for WellBiome® with Draco Ingredients GmbH
09 July
Result of AGM
06 July
Extension of terms for WellBiome®
01 July
Distribution agreement with Actial Farmaceutica
29 June
Launch of WellBiome
17 June
Notice of Annual General Meeting
03 June
Exercise of Warrant and Issue of Equity
02 June
Grant of Options
01 June
Holding(s) in Company
01 June
Appointment of Cambridge Commodities as UK distributor
28 May
Final Results for 13 months to 31 December 2019
20 May
Launch of SlimBiome® containing gummies in the USA
18 May
Trading and commercial update
11 May
Exclusive distribution agreement with MAXCARE Inc. for SlimBiome® in Taiwan
05 May
Distribution of products in China and Hong Kong
04 May
Non-exclusive agreement with Smart For Life
17 April
Holding(s) in Company
17 April
Placing and Related Party Transaction
06 April
SlimBiome® contract manufacturing agreement with Laboratoire PYC Inc.
02 April
SlimBiome® contract manufacturing agreement with Fipros A/S
31 March
Exclusive licence agreement for OptiBiome® with OptiPharm Pty Ltd.
24 March
Extension of territories for GoFigure® with Extensor
23 March
Change of accounting year end
17 March
Exclusive Distribution Agreement for SlimBiome® Medical
16 March
Director's Dealing
12 March
New partner for LPLDL® in Bulgaria
11 March
Extension of LPLDL® supply agreement with SACCO S.r.l.
25 February
Marketing update
17 February
Appointment of Advanced NutriSolutions Inc./Select Ingredient as exclusive distributor for LPLDL® in the United States and Canada
12 February
Extension of LPLDL® into Dairy Products
31 January
Launch of SlimBiome® in North America with Agropur Inc.
28 January
Extension of term and territories for SlimBiome®, SlimBiome® Medical and GoFigure®
27 January
Launch of LPLDL® product with AlfaSigma
17 January
Year-end Update
08 January
Human study shows formulation with LPLDL® reduces high blood pressure
07 January
Launch of a SlimBiome® containing product range with Holland & Barrett

2019

19 December
SlimBiome® distribution agreement for Germany
17 December
Anthem BioPharma launches two products formulated with SlimBiome® to the Indian market
09 December
Distribution agreement for CholBiome®x3 in the Philippines
06 December
GoFigure® and SlimBiome® commercial updates
05 December
Unflavoured SlimBiome® Medical granted medical device status and CE mark
04 December
Appointment of European Sales Leader for ProBiotix Health Ltd
09 October
LPLDL® Pharmaceutical GMP process validation
18 September
GoFigure® distribution agreement for Southern Africa
28 August
Director's Dealing
28 August
Holding(s) in Company
28 August
Directorate Change
28 August
Half Year Report
12 August
Manufacturing, supply and profit sharing agreement with Maxum Foods Pty Ltd.
29 July
Transfer of certain SkinBioTherapeutics plc shares
18 July
Online distribution agreement for SlimBiome® Medical
11 July
Scientific and commercial update
03 July
License agreement for LPLDL® in Japan
01 July
LPLDL® license agreement with Kappa Bioscience AS for vascular health product
25 June
Appointment of goetzpartners securities Limited
24 June
Manufacturing, supply and profit sharing agreement with Agropur MSI, LLC
11 June
Result of AGM
10 June
License agreement for CholBiome® and CholBiome®x3 in Vietnam
29 May
Director's Dealing
28 May
Appointment of CEO for ProBiotix Health Ltd
22 May
GoFigure® distribution agreement for Poland
20 May
LPLDL® license agreement for new application in hypertension
17 May
Notice of AGM
14 May
Distribution Agreement for SlimBiome® in Thailand
07 May
License agreement for LPLDL® in personalised nutrition applications
02 May
Investor evening
01 May
OptiBiotix to launch SlimBiome® Medical to the EU market at Vitafoods Europe 2019
29 April
Final Results
24 April
SlimBiome® Medical launches in UK market
11 April
SlimBiome® receives approval from FSSAI in India
09 April
SlimBiome® Medical agreement for Bulgaria
27 March
Grant of Options
27 March
SweetBiotix®: Scientific and commercial update
20 March
Exclusive distribution agreement for SlimBiome®
15 March
Extension of term and territories for LPLDL® capsules with HLH Biopharma GmbH
13 March
Exercise of Warrants and Issue of Equity
21 February
LPLDL® determined GRAS by an Expert Panel in the United States
20 February
Presentations at ProBiota - 2019
13 February
Year-end Update
11 February
Distribution agreement for Lactobacillus plantarum LPLDL® in Japan
07 February
Supply agreement for LPLDL® in the Baltic States
18 January
Exercise of Warrants and Issue of Equity
11 January
Director Appointment
09 January
Distribution agreement for cholesterol reducing CholBiome®
07 January
Manufacturing, supply and profit sharing agreement for SlimBiome®

2018

17 December
Directorate Change and Appointment of Managing Director of OptiBiotix's prebiotic division
14 December
Issue of Convertible Loan Notes by ProBiotix and Related Party Transaction
05 December
Holding(s) in Company
04 December
SlimBiome® Medical agreement for Greece and Cyprus
29 November
SlimBiome Medical Exclusive Manufacturing Agreement
27 November
SlimBiome® granted medical device status and CE mark
22 November
CholBiome® agreement for Greece and Cyprus
11 October
Director's dealing
09 October
LPLDL® US manufacturing and supply agreement
08 October
Exercise of Options, Director's Dealing and Issue of Equity
03 October
Non-exclusive distribution agreement for SlimBiome®
01 October
Non-exclusive distribution agreement for SlimBiome®
26 September
Distribution agreement for cholesterol reducing CholBiome®
25 September
Grant of Options and PDMR Dealing
24 September
Formation of ProBiotix Health Limited and Appointment of Adam Reynolds as Chairman
10 September
Director Appointment
10 September
Exercise of Warrants and Issue of Equity
10 September
Licence agreement with Bened Biomedical
04 September
OptiBiotix signs US pharmaceutical deal for its cholesterol reducing Lactobacillus plantarum strain
30 August
Half Yearly Report
31 July
Director's dealing
17 July
Grant of Options
12 July
Director's dealing
06 July
Holding(s) in Company
04 July
Result of AGM
04 July
Directorate change
26 June
Agreement with global corporate for SweetBiotix®
21 June
Exclusive license agreement for LPLDL®
18 June
Manufacturing, supply and profit sharing agreement with Morley Foods
14 June
Exercise of Options and Issue of Equity
11 June
Notice of AGM
07 June
US launch of LPLDL® with Seed Health
31 May
SweetBiotix®: Evaluation agreement with global dairy company
30 May
Placing and Issue of Equity
23 May
Final Results
22 May
LP-LDL® agreement for USA
18 May
SlimBiome® wins award at Vitafoods 2018
16 May
Holding(s) in Company
16 May
Exclusive manufacturing and supply agreement
08 May
Launch of extended range of LPLDL® and SlimBiome® products at Vitafoods 2018
01 May
LP-LDL® news media interest in USA
30 April
Notice of Results
24 April
Non-Exclusive UK distribution agreement for SlimBiome®
19 April
Appointment of Head of Online Sales and Marketing
18 April
Exclusive distribution agreement with Trigen Pharma for CholBiome®
05 April
New patent filings: SweetBiotix®
27 March
Scientific and commercial update
08 March
Launch of Slimbiome® in Nutri-bites®
06 March
LPLDL® Exclusive European License Agreement
28 February
OptiBiotix Capital Reorganisation
06 February
Exercise of warrant and issue of equity
01 February
Director's dealing
30 January
Exercise of warrant and issue of equity
25 January
Result of GM
23 January
SweetBiotix® development: Results of further human taste studies
17 January
Presentation of research data at European Conference: ProBiota 2018
08 January
Shareholder Circular and Notice of General Meeting
08 January
Directorate changes

2017

14 December
Exercise of Warrant and Issue of Equity
12 December
SlimBiome® USA manufacturing, supply and profit sharing agreement
05 December
Proposed directorate changes
28 November
Capital reorganisation: Potential for future dividend payments
17 November
Exercise of Warrant and Issue of Equity
08 November
SlimBiome® commercial and product development update
02 November
Rapidly Transitioning to Commercial Phase
01 November
Manufacturing, supply and profit sharing agreement with Knighton Foods
26 October
Presentation of research at MicroBiome R&D and Business Collaboration: USA
24 October
LPLDL® supply agreement with Galenicum
04 October
Successful launch of LPLDL® and SlimBiome® products at Supply Side West 2017
19 September
SlimBiome®: Technical, Regulatory and Commercial Update
13 September
Strategic partnership with Bened Biomedical
11 September
Holding(s) in Company
07 September
OptiBiotix invited to present at Expoquimia in Barcelona
06 September
Investor evening
05 September
Scale up and Manufacturing Agreement with Tata Chemicals
01 September
Exercise of Option and Issue of Equity
30 August
Half Yearly Report
24 August
US product launch of LPLDL® at Supply Side West trade show
22 August
Global manufacturing and supply agreement with Sacco S.r.l.
31 July
Total Voting Rights
26 July
Market launch for LPLDL® capsules in Germany
17 July
LPLDL® supply agreement for New Zealand & Australia with Pharmabiota Ltd
11 July
SweetBiotix® development: Results of human taste study
06 July
Grant of Options
15 June
Result of AGM
15 June
Supply agreement for LPLDL® capsules with HLH Biopharma GmbH
31 May
Holding(s) in Company
16 May
Successful Launch of LPLDL® and SlimBiome® products at Vitafoods 2017
09 May
LPLDL® Non-Exclusive European License Agreement
03 May
Presentation of abstract at Probiotics and Prebiotics conference
25 April
First sales of LPLDL® to German market
25 April
Final Results and Notice of AGM
04 April
Notice of Results Analyst and Investor Briefing
29 March
UK Investor Show attendance
24 March
Holding(s) in Company
21 March
Intention to float SkinBiotherapeutics
15 March
Confirmation of Director appointments to the Board
08 March
European manufacturing, supply and profit sharing agreement
01 March
Launch of products at Vitafoods 2017
08 February
Exercise of Warrants and Issue of Equity
26 January
Result of General Meetings of Warrant Holders
18 January
Appointment of Sales and Marketing Director
17 January
Holding(s) in Company
13 January
Exercise of Option and Issue of Equity
11 January
Exercise of Warrants and Issue of Equity
05 January
Appointment of New Commercial Director
03 January
Increased investment in The Healthy Weight Loss Company Ltd

2016

23 December
Notice of General Meeting of Warrant Holders
13 December
Joint Product Agreement with multinational
01 December
Exercise of Warrants and Issue of Equity
29 November
Scientific and Commercial Update
03 November
Presentation of research data at European Microbiome Summit
26 October
Scientific and Commercial Update
20 October
Optibiotix increased investment in SkinBiotix Limited
05 October
Appointment of Chairman and Director for SkinBiotix Limited
28 September
Appointment of Broker
23 September
Exercise of Warrants and Issue of Equity
14 September
Holding in Company
06 September
Consumer Survey of GoFigure® products
25 August
Half Yearly Report
12 August
Exercise of Warrants and Issue of Equity
09 August
First products in Whole Foods Market Inc
03 August
Notice of Results
02 August
Appointment of Director of Business Development
28 July
Holding(s) in Company
26 July
Slimbiome®: Successful completion of pilot launch in GoFigure® shakes and bars
14 July
New patent filing: Combination ingredients to reduce cardiovascular risk factors
05 July
Strategy Update
04 July
Holding(s) in Company
30 June
Exercise of Warrants and Issue of Equity
02 June
Exercise of Warrants and Issue of Equity
19 May
New patent filing: Antimicrobial Resistant (AMR) Health Care Acquired Infections
10 May
Result of Annual General Meeting
20 April
Exercise of Warrants and Issue of Equity
14 April
Final Results and Notice of AGM
07 April
Results of cholesterol human volunteer study
05 April
Joint Development Agreement signed with Royal DSM
24 March
Exercise of Warrants and Issue of Equity
23 March
Notice of Results
22 March
Second Contract signed with Instituto de Química Orgánica General, Spain
17 March
Joint venture agreement with the University of Manchester
26 February
Exercise of Warrants and Issue of Equity
19 February
Exercise of Warrants and Issue of Equity
12 February
Exercise of Warrants and Issue of Equity
05 February
Placing
28 January
Investor Presentation - Change of venue
26 January
Exercise of Warrants and Issue of Equity
20 January
Investor Presentation
19 January
Professor Tim Spector joins Scientific Advisory Group
13 January
Commercial Agreement signed with KSF Acquisition UK Limited

2015

21 December
Completion of Placing & Total Voting Rights
11 December
Exercise of Warrants and Issue of Equity
07 December
Placing and Directors' Dealings
24 November
Directorate Change Appointment of Peter Wennström as Non-Executive Director
20 November
Development Agreement signed with Centro Sperimentale del Latte
16 November
Exercise of Warrants and Issue of Equity
03 November
New patent filings
07 October
Holding(s) in Company
07 October
New microbial strain registrations
29 September
Completion of Human studies and commencement of pilot manufacturing studies
18 September
Exercise of Warrants and Issue of Equity
27 August
Half Yearly Report
11 August
Result of AGM
28 July
Completion of Human Studies
09 July
Contract signed with Instituto de Química Orgánica General
23 June
Holding(s) in Company
17 June
Exercise of Warrants and Issue of Equity
12 June
Holding(s) in Company
09 June
OptiBiotix and Venture Life to enter a Strategic Development and Commercial Alliance
05 June
Exercise of Warrants and Issue of Equity
03 June
Holding(s) in Company
02 June
Contract signed with multinational consumer goods company
29 May
Final Results for the year ended 30 November 2014 and Notice of AGM
28 May
New patent filings
26 May
Exercise of Warrants and Issue of Equity
15 May
Holding(s) in Company
13 May
Notice of Results
21 April
Exercise of Warrants and Issue of Equity
17 April
Research Update
14 April
UK Investor Show attendance
08 April
Holding(s) in Company
31 March
Grant of Options
25 March
Holding(s) in Company
20 March
Exercise of Warrants and Issue of Equity
10 March
Contract signed with NIZO Food Research
23 February
Investor Teach-In
18 February
Board Appointment
04 February
Holding(s) in Company
21 January
Joint venture agreement with NIP B.V., a wholly owned undertaking of NIZO Food Research
20 January
Exercise of Warrants and Issue of Equity
15 January
Additions to Scientific Advisory Group
09 January
Exercise of Warrants and Issue of Equity

2014

15 December
Successful completion of ethics approval and study recruitment
10 December
Appointment of Joint Broker
02 December
Successful completion of pre-clinical studies
28 November
Holding(s) in Company
28 November
OptiBiotix showcases weight management product at Health Ingredients Europe
27 November
Exercise of Warrants and Issue of Equity
25 November
OptiBiotix showcases weight management product at Health Ingredients Europe
18 November
Appointment of Head of Research and Development
14 November
Exercise of Warrants
11 November
Contract signed with Reading University for start of clinical studies
28 October
Successful incorporation of weight management formulation in yoghurts
20 October
OptiBiotix Announces Formation of Scientific Advisory Group
01 October
Exercise of Warrants
17 September
Contract signed with Nizo Food Research
05 August
First day of dealings on AIM
04 August
Change of name to OptiBiotix Health Plc
04 August
Result of General Meeting
18 July
Exercise of warrants and issue of equity
18 July
Schedule 1 - Ducat Ventures plc
18 July
Restoration - Ducat Ventures plc
18 July
Publication of Admission Document & Restoration of Trading on AIM
18 July
Half Yearly Report
09 May
Temporary Suspension
09 May
Suspension - Ducat Ventures Plc
24 February
Results of Annual General Meeting
20 February
Results of Open Offer and Issue of Equity
03 February
Further re Open Offer
30 January
Offer Document Posted
30 January
Final Results for the sixteen months to 30 November 2013 and Notice of Annual General Meeting

2013